The first sign that the morning was going wrong was not the missing document case.
It was the way the rain started.
Chicago rain in late October could arrive with theater or with stealth. That morning it came like a decision already made—thin at first, then harder, needling the black town cars lined up in front of the Archer Tower, turning the sidewalks reflective and cold.
Mara Sorrell watched it through the rear passenger window while the driver eased toward the curb.
Her phone buzzed again.
Daniel Reeve.
She let it vibrate twice before answering. “I’m here.”
“We’re all set upstairs,” her CFO said. “Buyers arrived early. Alan wants to move quickly before the market starts reacting to the leak.”
“It wasn’t a leak,” Mara said.
A pause.
Then Daniel chose his words carefully. “It was an article saying your company is considering strategic alternatives. That’s close enough.”
Mara looked at her reflection in the dark glass. Navy suit. Hair pinned back. No visible exhaustion, despite sleeping barely three hours.
“Did the final notarized addendum get logged?” she asked.
“Yes.”
“Scanned?”
“I have the backup copy in the data room.”
“Backup doesn’t close the deal. The original does.”
“I know.”
There was a subtle edge in his voice now, something she noticed but did not stop to examine. “Mara, you don’t have to remind me what’s at stake.”
The car stopped. Rain rattled harder against the roof.
“Good,” she said, and ended the call.
For a moment she stayed where she was.
This acquisition was supposed to be a rescue, though everyone dressed it in cleaner language. Partnership. Strategic transaction. Shared growth. The truth was uglier. Sorrell Biotech had brilliant science, a respected oncology platform, and eight hundred employees who believed they were changing lives. It also had eighteen months of brutal trial delays, supply chain overruns, and debt covenants closing in like fists.
The buyer, Halcyon Ventures, had money. Deep money. Enough to stabilize manufacturing, preserve the flagship treatment program, and prevent the layoffs Mara had been avoiding for six months.
In exchange, Mara would lose control of the company she had built from a rented lab with secondhand centrifuges and three people willing to work for stock options and caffeine.
She had told herself that control was a vanity and survival was not.
Some days she believed it.
The driver opened her door and raised an umbrella.
She stepped out with her graphite-gray document case in one hand and her phone in the other. Security moved toward the entrance. The revolving door turned. A courier brushed past. Someone called her name from the sidewalk—one of the younger analysts, maybe—but she didn’t look.
Everything blurred into motion.
Then elevator. Lobby. Badge. Reception.
Forty floors later, the future of her company was waiting in a glass box above the city.
The boardroom looked exactly as it always did: expensive enough to intimidate, tasteful enough to pretend otherwise. Walnut table. Architectural lighting. A wall of rain-streaked windows framing the river and the steel-gray horizon. Bottled water placed at measured angles. A screen at one end with the closing agenda glowing in pale blue.
Twelve people sat around the table.
Daniel was near the center, already standing when she entered. He gave her a small nod. He looked immaculate: charcoal suit, silver
